Anti-Phosphatidylethanolamine Panel
Use
The Anti-Phosphatidylethanolamine Panel tests for anticardiolipin antibodies (aCL), which are associated with a variety of conditions including systemic lupus erythematosus, recurrent pregnancy loss, and thrombotic events. The presence of aCL is used in diagnosing antiphospholipid syndrome (APS) by evaluating the presence of antibodies that target phosphatidylethanolamine, a lipid component in the blood. This test is essential for understanding patients' risk for abnormal blood clotting or miscarriage due to autoimmune activity and managing their condition effectively.
Special Instructions
Not provided.
Limitations
The assay may not detect all cases of antiphosphatidylethanolamine antibodies depending on their concentration in the serum. False positives or negatives can occur due to cross-reactivity with other antibodies or improper specimen handling. Hemolysis, lipemia, and icterus can interfere with results, necessitating rejection of such samples. Clinical correlation with patient history and other diagnostic findings is recommended to confirm diagnosis.
New York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 13076-5 - PE IgG Ser-aCnc
- 13077-3 - PE IgM Ser-aCnc
- 13078-1 - PE IgA Ser-aCnc
Result Turnaround Time
3-11 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
3 mL
Minimum Volume
0.5 mL
Container
Plastic vial
Collection Instructions
Allow blood to clot for 30 minutes. Centrifuge and aliquot 3 mL of serum into a plastic vial. Send frozen.
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus, and microbial contamination are causes for rejection.
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 14 days |
| Frozen | 30 days |